175,000 IDEAYA (IDYA) stock options granted to Chief Medical Officer

Rhea-AI Filing Summary

IDEAYA Biosciences’ Chief Medical Officer, Darrin Beaupre, reported a new stock option grant. On January 30, 2026, he received a stock option to buy 175,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.

The option vests over four years starting from January 1, 2026: 25% of the shares vest on the first anniversary, then 1/48th of the total shares vest monthly so that the grant is fully vested and exercisable on the fourth anniversary of the vesting commencement date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Beaupre Darrin

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	175,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 175,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beaupre Darrin

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$32.19	01/30/2026		A		175,000		(1)	01/30/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Joshua Bleharski, as Attorney-in-Fact for Darrin Beaupre	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IDEAYA Biosciences (IDYA) disclose in this Form 4?

IDEAYA Biosciences reported a stock option grant to its Chief Medical Officer, Darrin Beaupre, covering 175,000 shares. The option was granted on January 30, 2026, and represents equity-based compensation rather than an open-market purchase or sale of existing IDEAYA shares.

How many IDEAYA (IDYA) shares are covered by the new stock option grant?

The new stock option grant to Chief Medical Officer Darrin Beaupre covers 175,000 shares of IDEAYA common stock. These shares are not owned outright at grant; they become exercisable over time as the vesting schedule milestones are reached by the reporting person.

What is the exercise price and term of the IDEAYA (IDYA) stock options granted?

The stock option has an exercise price of $32.19 per share and expires on January 30, 2036. This means Beaupre can, once vested, buy shares at $32.19 any time before expiration, subject to the option’s other terms and conditions described in the grant.

How do the IDEAYA (IDYA) options granted to the CMO vest over time?

Vesting starts from January 1, 2026. Twenty-five percent of the shares vest on the first anniversary, then one-forty-eighth of the total shares vest monthly. This schedule continues until the grant is fully vested and exercisable on the fourth anniversary of the vesting commencement date.

Is the IDEAYA (IDYA) Form 4 transaction a purchase, sale, or grant of options?

The Form 4 reports a grant of derivative securities, specifically a stock option described as a right to buy IDEAYA common stock. The transaction code is “A,” and the reporting shows 175,000 derivative securities acquired directly, not a market trade in existing common shares.

Who is the insider involved in this IDEAYA Biosciences (IDYA) Form 4 filing?

The insider is Darrin Beaupre, who serves as Chief Medical Officer of IDEAYA Biosciences. He is identified as an officer, not a director or 10% owner. The reported transaction reflects equity compensation granted to him in the form of stock options.